Voyager Therapeutics (VYGR) Operating Margin (2015 - 2026)
Voyager Therapeutics (VYGR) reported Operating Margin of 1167.37% for Q1 2026, down 63141.0% on a YoY basis from N/an in Q1 2025, and down 499.6% sequentially from 194.69% in Q4 2025.
Voyager Therapeutics (VYGR) Operating Margin (2015 - 2026) Analysis & Trends
Voyager Therapeutics (VYGR) has 12 years of Operating Margin data on file, last reported at 1167.37% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin fell 63141.0% year-over-year to 1167.37%; the trailing twelve-month figure through Mar 2026 stood at 348.79% (down 19681.0% YoY), and the FY2025 full-year result was 326.56%, down 22245.0% from the prior year.
- Operating Margin fell to 1167.37% in Q1 2026, from 194.69% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 1584.71% in Q4 2022 to a low of 3244.68% in Q1 2022.
- A 5-year average of 528.85% and a median of 228.91% in 2025 frame the typical range for Operating Margin.
- Across the five-year window, Operating Margin sank 285106 bps in 2022 and jumped 332634 bps in 2023, its largest moves.
- Tracing VYGR's Operating Margin over 5 years: stood at 1584.71% in 2022, then slumped by 96 bps to 60.0% in 2023, then sank by 1113 bps to 607.82% in 2024, then soared by 68 bps to 194.69% in 2025, then slumped by 500 bps to 1167.37% in 2026.
- Business Quant data shows VYGR's Operating Margin at 1167.37% in Q1 2026, 194.69% in Q4 2025, and 228.91% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Voyager Therapeutics | 183.84 Mn | 42.36 Mn | - | -1,167.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,167.37% |
| Dec 31, 2025 | -194.69% |
| Sep 30, 2025 | -228.91% |
| Jun 30, 2025 | -704.33% |
| Mar 31, 2025 | -535.96% |
| Dec 31, 2024 | -607.82% |
| Sep 30, 2024 | -55.95% |
| Jun 30, 2024 | -50.80% |
| Mar 31, 2024 | -82.99% |
| Dec 31, 2023 | 60.00% |
| Sep 30, 2023 | -639.51% |
| Jun 30, 2023 | -518.90% |
| Mar 31, 2023 | 81.66% |
| Dec 31, 2022 | 1,584.71% |
| Sep 30, 2022 | 35.15% |
| Jun 30, 2022 | -2,720.08% |
| Mar 31, 2022 | -3,244.68% |
| Dec 31, 2021 | 20.31% |
| Sep 30, 2021 | -1,696.76% |
| Jun 30, 2021 | -2,106.48% |